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Background: The eligibility of breast cancer patients for human epidermal growth factor receptor 2 (HER2)-directed
therapies is determined by the HER2 gene amplification and/or HER2 protein overexpression status of the breast
tumor as determined by in situ hybridization (ISH) or immunohistochemistry (IHC), respectively. Our objective was
to combine the US Food and Drug Administration (FDA)-approved HER2 & chromosome 17 centromere (CEN17)
brightfield ISH (BISH) and HER2 IHC assays into a single automated HER2 gene-protein assay allowing simultaneous
detection of all three targets in a single tissue section.
Methods: The HER2 gene-protein assay was optimized using formalin-fixed, paraffin-embedded (FFPE) samples of
the xenograft tumors MCF7 [HER2 negative (non-amplified gene, protein negative)] and Calu-3 [HER2 positive
(amplified gene, protein positive)]. HER2 IHC was performed using a rabbit monoclonal anti-HER2 antibody (clone
4B5) and a conventional 3,3'-diaminobenzidine IHC detection. The HER2 & CEN17 BISH signals were visualized using
horseradish peroxidase-based silver and alkaline phosphatase-based red detection systems, respectively with a
cocktail of 2,4-dinitrophenyl-labeled HER2 and digoxigenin-labeled CEN17 probes. The performance of the
gene-protein assay on tissue microarray slides containing 189 randomly selected FFPE clinical breast cancer tissue
cores was compared to that of the separate HER2 IHC and HER2 & CEN17 BISH assays.
Results: HER2 protein detection was optimal when the HER2 IHC protocol was used before (rather than after) the
BISH protocol. The sequential use of HER2 IHC and HER2 & CEN17 BISH detection steps on FFPE xenograft tumor
sections appropriately co-localized the HER2 protein, HER2 gene, and CEN17 signals after mitigating the silver
background staining by using a naphthol phosphate-containing hybridization buffer for the hybridization step. The
HER2 protein and HER2 gene status obtained using the multiplex HER2 gene-protein assay demonstrated high
concordance with those obtained using the separate HER2 IHC and HER2 & CEN17 BISH assays, respectively.
Conclusions: We have developed a protocol that allows simultaneous visualization of the HER2 IHC and HER2 &
CEN17 BISH targets. This automated protocol facilitated the determination of HER2 protein and HER2 gene status in
randomly selected breast cancer samples, particularly in cases that were equivocal or exhibited tumor
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heterogeneity. The HER2 gene-protein assay produced results virtually equivalent to those of the single
FDA-approved HER2 IHC and HER2 & CEN17 BISH assays.
Virtual slides: The virtual slides for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
2041964038705297
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Breast cancer is the most common cause of cancer death in
Europe and the second leading cause of cancer death in the
United States. The oncogene HER2, which encodes human
epidermal growth factor receptor 2 (HER2) protein, is amp-
lified in 20–30% of breast cancer cases [1] and is the target
of HER2-directed anti-cancer therapies. Trastuzumab
(Herceptin; Genentech, South San Francisco, CA, USA), a
humanized monoclonal anti-HER2 antibody, has thera-
peutic effects against HER2 gene and/or HER2 protein posi-
tive breast cancers as an adjuvant therapy. The small
molecule dually targeted drug Lapatinib (Tyverb/Tykerb;
GlaxoSmithKline, London, United Kingdom), which inhibits
the tyrosine kinase activities of the HER2 and of epidermal
growth factor receptor (EGFR) proteins, is a first-line thera-
peutic agent against triple positive breast cancers (positive
for HER2 protein, estrogen receptor, and progesterone re-
ceptor) and it is also used in treating breast cancers refrac-
tory to trastuzumab therapy. Several drugs are currently in
Phase III clinical trials for treatment of HER2 positive breast
cancer, including pertuzumab, neratinib, and afatinib.
The American Society of Clinical Oncology (ASCO) and
the College of American Pathologists (CAP) have intro-
duced guidelines for HER2 status assessments based on
the level of HER2 protein overexpression determined by
immunohistochemistry (IHC) and on the level of HER2
gene amplification determined by in situ hybridization
(ISH) on formalin-fixed, paraffin-embedded (FFPE) breast
cancer tissue sections [2]. However, which of the two
methods is superior for assessing the HER2 status of
breast cancer patients is unclear.
The two HER2 IHC-based diagnostic tests for assessing
HER2 protein expression that are approved by the US
Food and Drug Administration (FDA) use either a rabbit
polyclonal (DAKO, Glostrup, Denmark) or a rabbit mono-
clonal (Ventana Medical Systems, Inc., Tucson, AZ, USA)
antibody against HER2 protein. The results of these tests
are scored semi-quantitatively as either 0 (negative), 1+
(negative), 2+ (equivocal), or 3+ (positive) [2]. The four
FDA-approved ISH diagnostic tests for quantifying HER2
gene copy numbers are dual color fluorescence ISH (FISH)
(Abbott Molecular, Illinois, USA), single color chromo-
genic ISH (CISH) (Invitrogen, California, USA), dual color
brightfield in situ hybridization (BISH) (Ventana), and dual
color CISH (Dako) assays. For the dual color assays, resultsare determined as the ratio of the HER2 gene signal to the
chromosome 17 centromere (CEN17) signal (negative:
HER2/CEN17< 1.8; equivocal: 1.8≤HER2/CEN17≤ 2.2;
positive: HER2/CEN17> 2.2) [2]. The results of single
color ISH assays are considered positive if they detect six
or more HER2 gene copies and negative if they detect
fewer than six [3].
HER2 gene status and HER2 protein expression are gen-
erally concordant in breast cancer [4]. However, discord-
ance between HER2 IHC and HER2 ISH assay results can
be caused by various factors and is not uncommon. For
example, variations in tissue processing protocols affect
HER2 protein detection more than the HER2 gene detec-
tion; thus ISH assays can be more accurate than IHC
assays when the pre-analytical process is not standardized
[4]. Tumor heterogeneity can also contribute to discord-
ance between HER2 IHC and HER2 ISH scoring [5]. The
possibility that a breast cancer patient will receive an
incorrect HER2 status assessment is decreased when
both assays are used, particularly when the cases are
equivocal [6].
The simultaneous brightfield detection of HER2 protein
and HER2 gene expression “HER2 gene-protein assay” in
FFPE breast cancer tissue sections has been previously
reported by three independent groups [7-9]. First, Downs-
Kelly et al. [7] successfully combined an alkaline phos-
phatase (AP)-based fast red dye system for HER2 IHC
with a horseradish peroxidase (HRP)-based silver depos-
ition system for HER2 ISH. Then, Ni et al. [8] combined a
fast red dye system for HER2 IHC with an HRP-based
3,3′-diaminobenzidine (DAB) system for HER2 ISH. In
the most recent report of a HER2 gene-protein assay, Rei-
senbichler et al. [9] used DAB-based detection for both
HER2 IHC and HER2 ISH in a single color HER2 gene-
protein assay. Co-localization of CEN17 was not included
in any of these HER2 gene-protein assays, even though
using the copy numbers of both the HER2 gene and
CEN17 is considered optimal in determining HER2 gene
status for possible anti-HER2 therapies [4]. Furthermore,
the previously described HER2 gene-protein assays were
performed with semi-automated protocols requiring some
manual steps.
In this study, our objectives were: 1) to develop an
automated HER2 gene-protein assay for simultaneous
tricolor visualization of HER2 protein, the HER2 gene,
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cancer cases and 2) to evaluate the performance of this
assay in determining the HER2 status of clinical breast
cancer tissues on tissue microarray (TMA) slides.
Methods
Tissue samples
FFPE MCF7 and Calu-3 xenograft tumors were used for
the initial development and optimization of the HER2
gene-protein assay. MCF7 is a breast adenocarcinoma
cell line in which the HER2 gene is not amplified (aver-
age copy number = 2) and Calu-3 is a lung adenocarcin-
oma cell line in which HER2 is amplified (average copy
number = 30) [10]. Paraffin sections of the tumors were
placed onto Superfrost Plus glass slides (Erie Scientific
Company, Portsmouth, NH, USA) for analysis.
The performance of the HER2 gene-protein assay was
examined using 189 breast cancer tissue cores on TMA
slide sets provided by the National Cancer Center Hos-
pital (NCCH), Tokyo, Japan. The breast cancer tissue
samples were randomly selected from a tissue archive of
samples acquired between 1991 and 1995. The protocol
was approved by the NCCH Institutional Review Board.
The TMA slides contained 36–41 tissue cores on a Mat-
sunami Platinum coated glass slide (Matsunami Glass
Ind., Ltd., Osaka, Japan). To orient the tissue cores and
provide a positive control, two tissue cores from a selected
HER2-amplified breast cancer case were included in each
TMA block. The adhesion of the tissue cores onto the
TMA slides was enhanced by baking the slides for 15 min
at 65°C before each assay.
IHC determination of HER2 protein expression
The FDA-approved HER2 IHC assay using PATHWAY
HER-2/neu rabbit monoclonal antibody (clone 4B5; Ven-
tana) was performed with iView DAB Detection Kit (Ven-
tana) on a BenchMark XT automated staining system
(Ventana). Briefly, the tissue sections were deparaffinized
with EZ Prep (Ventana) at 75°C, heat pretreated in Cell
Conditioning 1 (CC1; Ventana) using “standard cell condi-
tioning” for antigen retrieval at 100°C, and then incubated
with the anti-HER2 primary antibody for 32 min at 37°C
after inactivation of the endogenous peroxidase with
hydrogen peroxide for 4 min. They were then blocked
using Endogenous Biotin Blocking Kit (Ventana), incu-
bated with a biotinylated secondary antibody for 8 min,
and incubated with a streptavidin-HRP conjugate for
8 min at 37°C. The immunolocalized HER2 protein was
visualized using a copper-enhanced DAB reaction. The
slides were counterstained with Hematoxylin II (Ventana)
for 4 min and Bluing Reagent (Ventana) for 4 min and cov-
erslips were applied by an automated coverslipper (Tissue-
Tek Film Automated Coverslipper; Sakura Finetek Japan,
Tokyo, Japan).Dual color BISH determination of HER2/CEN17 ratio
The FDA-approved dual color BISH assay (INFORM
HER2 Dual ISH DNA Probe Assay; Ventana) for HER2
and CEN17 quantitation was also performed on the Bench-
Mark XT using HER2 and CEN17 probes labeled with 2,4-
dinitrophenyl (DNP) and digoxigenin (DIG), respectively.
Briefly, after the tissue cores were deparaffinized with EZ
Prep at 75°C, they were subjected to three 12 min cycles of
heat pretreatment at 90°C in EZ Prep-diluted Cell Condi-
tioning 2 (CC2; Ventana) followed by protease digestion
with ISH Protease 3 (Ventana) for 16 min at 37°C. The
genomic DNA in tissue sections and the nick-translated
HER2 and CEN17 probes were co-denatured by heat treat-
ment for 20 min at 80°C followed by a hybridization step
for 6 h at 44°C. After three 8 min stringency washes were
carried out in 2× SSC (Ventana) at 72°C, the HER2 and
CEN17 signals were detected using ultraView SISH DNP
and ultraView Red ISH DIG Detection Kits (Ventana),
respectively.
For HER2 gene detection, the slides were incubated with
a rabbit anti-DNP antibody for 20 min and then with a
HRP-conjugated goat anti-rabbit antibody for 16 min at
37°C. The HER2 BISH signal was detected as metallic silver
deposits with silver acetate, hydroquinone, and hydrogen
peroxide for 4 min at 37°C. For CEN17 detection, the slides
were incubated with a mouse anti-DIG antibody for
20 min and then with an AP-conjugated goat anti-mouse
antibody for 32 min at 37°C. The CEN17 BISH signal was
developed as red dot staining with fast red and naphthol
phosphate for 16 min. Finally, the slides were counter-
stained with Hematoxylin II for 8 min and with Bluing
Reagent for 4 min. After the slides were rinsed and air-
dried, coverslips were applied by the Tissue-Tek Film
Coverslipper.
Development and optimization of the HER2 gene-protein
assay
The HER2 gene-protein assay was developed on the
BenchMark XT using FFPE xenograft tumors and clinical
breast cancer samples. The samples were stained under a
variety of assay conditions to determine an optimum
protocol needed to achieve HER2 protein, HER2 gene, and
CEN17 staining results comparable to those of the indi-
vidual HER2 IHC and HER2 & CEN17 BISH assays.
Optimum signal detection in the HER2 gene-protein assay
was achieved by performing the IHC procedure before the
BISH procedure. Reagent lots were consistent for all
TMA slides across all assays and all assays were com-
pleted within one week.
The breast cancer TMA slides were subjected to the
final optimized HER2 gene-protein staining protocol after
the paraffin-embedded tissue cores were deparaffinized
with a Liquid Coverslip (Ventana)-primed EZ Prep
method. For HER2 protein staining, the TMA slides were
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100°C and endogenous peroxidase was inactivated by in-
cubation with hydrogen peroxide for 4 min at 37°C. The
tissue cores were incubated with the rabbit monoclonal
anti-HER2 antibody for 32 min at 37°C and the endogen-
ous biotin was blocked using Endogenous Biotin Blocking
Kit. The slides were incubated with a biotinylated second-
ary antibody for 8 min and then with a HRP-conjugated
streptavidin for 8 min at 37°C. A copper enhanced DAB
reaction was used to visualize the HER2 protein.
For HER2 gene & CEN17 staining, the TMA slides
were subjected to three 12 min cycles of heat pretreat-
ment in EZ Prep-diluted CC2 at 90°C and then to mild
tissue digestion with ISH Protease 3 for 16 min at 37°C.
The tissue samples were then hybridized with a cocktail
of DNP-labeled HER2 and DIG-labeled CEN17 probes at
44°C for 6 h after denaturing for 4 min at 80°C. Hyb-
Clear blocking solution (Ventana), a hybridization buffer
containing naphthol phosphate, was added to the probe
cocktail to block the interaction between the DNP hap-
ten on the HER2 probe and the DAB deposit during
hybridization. Three 8 min stringency washes were car-
ried out in 2× SSC at 72°C.
For HER2 gene detection, the tissue samples were
incubated with a rabbit anti-DNP antibody for 20 min
at 37°C followed by incubation with a HRP-conjugated
goat anti-rabbit antibody for 24 min at 37°C. HER2
BISH signal was developed for 8 min by the metallic
silver deposit with silver acetate, hydroquinone, and
hydrogen peroxide. For CEN17 detection, the slides
were incubated with a mouse anti-DIG antibody for
20 min at 37°C followed by an AP-conjugated goat
anti-mouse antibody incubation for 32 min at 37°C.
CEN17 BISH signal was developed with a fast red
and naphthol phosphate mixture for 12 min at 37°C.
HER2 gene-protein slides were counterstained with
Hematoxylin II for 8 min followed by Bluing Reagent
for 4 min at 37°C. Air-dried slides were coverslipped
with the film coverslipper.Table 1 Joint Frequency Table for HER2 Staining Status
Comparator Y
y+ y−
Comparator X x+ a b
x− c dEvaluation of HER2 gene-protein assay performance
All tissue cores stained for the HER2 IHC, HER2 &
CEN17 BISH, and HER2 gene-protein assays were manu-
ally scored by three pathologists (MP, NW, PB). Two of the
pathologists were experienced at scoring HER2 IHC and
HER2 & CEN17 BISH slides whereas the third was trained
by reading the scoring guidelines immediately before scor-
ing. In the HER2 IHC assay and HER2 gene-protein assay,
tissue cores on TMA slides were scored for HER2 protein
expression from 0 to 3+. In the HER2 & CEN17 BISH
assay and the HER2 gene-protein assay, HER2 gene and
CEN17 copy numbers were collected for calculating the
ratio of HER2/CEN17 according to the scoring guideline.All data analyses were conducted using SAS 9.2 soft-
ware (SAS Institute Inc., Cary, North Carolina, USA).
Continuous variables were summarized descriptively by
sample size, mean, standard deviation (SD), median,
minimum, and maximum. Discrete variables were sum-
marized descriptively using counts and percentages.
Assay results were treated as positive or negative as pre-
viously approved by the FDA: 1) HER2 IHC negative (0
or 1+) and positive (2+ or 3+) and 2) HER2 & CEN17
BISH positive (HER2/CEN17 ratio ≥ 2.0) and negative
(HER2/CEN17 ratio< 2.0).
The concordance of the results from pairs of readers
and among pairs of tests was calculated according to the
following (Table 1):
Where x+ is the number of X positive samples, x− is
the number of X negative samples, y+ is the number of
Y positive samples, y− is the number of Y negative sam-
ples, a is the number of x+y+ samples, b is the number
of x+y− samples, c is the number of x−y+ samples, and d
is the number of x−y− samples.
For analyses in which comparator X was a “test” group
and comparator Y was a “reference” group (e.g., X was
the HER2 gene-protein test and Y was the HER2 IHC
test), concordance was assessed by calculating positive
percent agreement (PPA) and negative percent agree-
ment (NPA) among comparators according to the fol-
lowing formulas:
PPA ¼ a= aþ cð Þ½   100%
NPA ¼ d= bþ dð Þ½   100%
When neither comparator was considered to be the
reference (e.g., X and Y were two different scorers), con-
cordance was determined by calculating average positive
agreement (APA) and average negative agreement
(ANA) according to the following formulas [11]:
APA ¼ 2a= 2aþ bþ cð Þ½   100%
ANA ¼ 2d= 2d þ bþ cð Þ½   100%
The overall concordance was calculated as the overall
percent agreement (OPA) for all concordance analyses
according to the formula:
OPA ¼ aþ dð Þ= aþ bþ cþ dð Þ½   100%
Two-sided 95% confidence intervals were calculated
using the score method. Kappa coefficients were calcu-
lated for assay agreements for each analysis.
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Development of the HER2 gene-protein assay
The optimized staining protocol for simultaneous
visualization of HER2 protein, the HER2 gene, and CEN17
on the same tissue is shown in Figure 1. As shown in the
figure, the HER2 IHC detection is performed before the
HER2 & CEN17 BISH detection, as this sequence was
found to be the most sensitive for HER2 protein detection
(data not shown). The major technical difficulties encoun-
tered in combining the DAB-based HER2 IHC assay and
the HER2 & CEN17 BISH assay, which uses a DNP-labeled
HER2 probe, were high background staining of the nuclei
and a change in the DAB staining appearance on FFPE tis-
sue sections (Figure 2A, B). When the BISH step was car-
ried out after the DAB-based IHC step, the DNP hapten
on the HER2 DNA probe bound non-specifically to nuclei
and to some of the DAB staining, thus producing silver
background staining during the BISH detection step for


































Figure 1 Scheme for simultaneous visualization of human epidermal
chromosome 17 centromere (CEN17) using a novel HER2 gene-protei
staining (IHC) with a rabbit monoclonal anti-HER2 antibody and a conventi
HER2 gene and CEN17 are localized by brightfield in situ hybridization (BISH
digoxigenin (DIG)-labeled CEN17 probe. The HER2 gene and CEN17 signals
peroxide reaction) and fast red (a fast red and naphthol phosphate reactiofailed to reduce this artifactual background staining (data
not shown), but the inclusion of naphthol phosphate in the
hybridization buffer during hybridization was found to
block DNP-DAB interaction, thereby eliminating the silver
background staining (Figure 2C, D).
The optimized HER2 gene-protein assay appropriately
stains clinical breast-cancer tissue samples
Using a previously FDA-approved HER2 IHC assay, we
identified clinical breast cancer tissue samples with HER2
expression scores of 3+ (Figure 3A, B, C), 2+ (Figure 3D,
E, F), 1+ (Figure 3G, H, I), and 0 (Figure 3J, K, L). As
expected, a previously FDA-approved HER2 and CEN17
BISH assay resulted in labeling of the HER2 gene and
CEN17 targets in the same area of each tissue core as
black and red dots, respectively (Figure 3B, E, H, K). The
optimized HER2 gene-protein assay (with naphthol phos-
phate) stained the HER2 protein, HER2 gene, and CEN17



















growth factor receptor 2 (HER2) protein, the HER2 gene, and the
n assay. First, HER2 protein is localized through immunohistochemical
onal 3,3′-diaminobenzidine (DAB)-based detection method. Then, the
) with a cocktail of 2,4-dinitrophenyl (DNP)-labeled HER2 probe and
are visualized with silver (a silver acetate, hydroquinone, and hydrogen
n), respectively.
Figure 2 Naphthol phosphate blocks silver background staining resulting from the HER2 & CEN17 BISH procedure. Images show HER2
gene-protein staining results obtained without (A, B) or with naphthol phosphate (C, D) on formalin-fixed, paraffin-embedded (FFPE) HER2-
negative MCF7 (A, C) and HER2-positive Calu-3 (B, D) xenograft tumors. In the absence of naphthol phosphate, non-specific silver deposition
from the HER2 BISH detection procedure obscures the BISH signals for the HER2 gene and CEN17 targets (A, B) whereas the use of a BISH
hybridization buffer containing naphthol phosphate eliminates the non-specific silver deposition (C, D). Some silver deposition was also seen in
DAB staining (A). In the absence of naphthol phosphate, non-specific silver deposition occurred in mouse cells (yellow asterisks) (A, B) and mouse
cells were confirmed without HER2 and CEN17 BISH signals by using naphthol phosphate (C, D). 60×.
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complete membrane staining in the 3+ sample (Figure 3A,
C), less complete membrane staining in the 2+ sample
(Figure 3D, F), faint membrane staining in the 1+ sample
(Figure 3G, I), and no staining in the 0 sample (Figure 3J,
L), and the HER2 gene and CEN17 targets appeared as
black and red dots, respectively. Thus, the multiplex
HER2 gene-protein assay co-localized the HER2 protein,
HER2 gene, and CEN17 targets appropriately.
Performance of the optimized HER2 gene-protein Assay
The optimized HER2 gene-protein assay in determining
both HER2 protein (IHC) and HER2 gene (BISH) status
simultaneously demonstrated the usefulness of the assay
on equivocal (2+) and negative (0) HER2 IHC samples
of different HER2 ISH statuses (Figure 4). It readily dis-
tinguished the HER2 ISH positive samples from the
HER2 ISH negative samples in both the IHC equivocal
(Figure 4A and B, respectively) and the IHC-negative
cases (Figure 4C and D, respectively).
For one breast cancer tissue core, the HER2 gene-protein
assay revealed the heterogeneity of HER2 protein status
with HER2 IHC 3+, 2+, and 1+ cell populations visible
within the same area (Figure 5A). It also showed that the
HER2 IHC 3+ cell population contained dispersed HER2
gene copies while the HER2 IHC 2+ and 1+ cell popula-
tions contained clustered HER2 gene copies. The HER2
gene-protein assay also detected the scattered HER2positive cell populations within a breast cancer tissue core
(Figure 5B). Isolated HER2 IHC positive and HER2 &
CEN17 BISH positive tumor cells surrounded by the inter-
stitial tissue were clearly visible (Figure 5B, insert).
Because six of the 189 breast tissue cores examined
contained no tumor cells (Table 2), all statistical analyses
were based on the 183 remaining tissue cores with
tumor cells. All of these cores yielded evaluable IHC
results (from both the single and combined assays) for
each of the three readers in this study (Table 2). For the
BISH results, the percentage of evaluable cores ranged
from 90.7% (Reader A, HER2 & CEN17 BISH) to 98.4%
(Reader C, HER2 gene-protein assay). The HER2 gene-
protein assay consistently yielded a higher number of
evaluable cores than the HER2 & CEN17 BISH assay, al-
though most of these were evaluable (Table 2). The su-
periority of the HER2 gene-protein assay over the HER2
& CEN17 BISH assay in yielding BISH results ranged by
reader from approximately 7% to 13%.
The HER2 IHC score distributions for the HER2 IHC
assay relative to the HER2 gene-protein assay were com-
parable for each reader and the distributions of positive vs.
negative HER2 IHC assessments were consistent from
assay to assay and also from reader to reader (Table 3).
For both types of HER2 IHC and for all readers, approxi-
mately 30% of HER2 IHC assessments were positive and
approximately 70% were negative (Table 3). For each
reader, the average HER2 gene count, CEN17 count, and
Figure 3 The HER2 gene-protein assay yields appropriate staining of HER2 protein, the HER2 gene, and CEN17 in FFPE clinical breast
cancer tissues. Tissues with HER2 IHC scores of 3+ (A–C), 2+ (D–F), 1+ (G–I), and 0 (J–L) were subjected to HER2 IHC assay (A, D, G, J), HER2 &
CEN17 BISH assay (B, E, H, K), or the HER2 gene-protein assay (C, F, I, L) using tissue microarray slides. HER2 IHC assay yielded the expected HER2
protein staining (A, D, G, J) and the separate HER2 & CEN17 BISH assay yielded the expected staining of the HER2 gene (black dots) and CEN17
(red dots) (B, E, H, K). The combined assay yielded both the appropriate HER2 protein staining and the appropriate HER2 gene and CEN17
staining (C, F, I, L). [All images 60×.].
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CEN17 BISH and the HER2 gene-protein assay, and the
HER2 gene amplification status was comparable between
the two assays (Table 4). The distribution of amplified vs.
non-amplified HER2 & CEN17 BISH assessments was
consistent from assay to assay and also from reader to
reader (Table 4). For both types of HER2 & CEN17 BISH
and for all readers, approximately 25–27% of samples were
HER2 amplified and approximately 67–72% were non-
amplified when unevaluable tissue cores were included in
the calculation of percentage (Table 4).
In concordance analyses, the HER2 IHC assay was
taken as the reference assay for the HER2 protein ex-
pression results of the HER2 gene-protein assay
(Table 5). The IHC positive agreement ranged from
97.9% (Reader B) to 100% (Readers A and C) and the
IHC negative agreement ranged from 97.8% (Reader B)
to 99.2% (Reader C). The overall agreement rangedfrom 97.8% (Reader B) to 99.5% (Reader C) and the
kappa coefficient ranged from 0.94 (Reader B) to 0.99
(Reader C). These excellent agreement rates indicate
that HER2 status diagnosis based on the HER2 IHC part
of the combined HER2 gene-protein assay is essentially
equivalent to that based on the individual HER2 IHC
assay.
In concordance analyses, the HER2 & CEN17 BISH
assay was taken as the reference assay for the HER2 &
CEN17 BISH results of the HER2 gene-protein assay
(Table 6). The HER2 & CEN17 BISH positive agreement
ranged from 94% (Reader B) to 95.6% (Reader A) and
the BISH negative agreement ranged from 96.2% (Reader
C) to 99.2% (Reader B). The overall percent agreement
ranged from 96% (Reader C) to 97.7% (Reader B) and
the kappa coefficient ranged from 0.89 (Reader C) to
0.94 (Readers A and B), indicating that the HER2 diag-
nosis based on the HER2 & CEN17 BISH part of the
Figure 4 Differentiation of HER2 gene status in HER2 protein equivocal (IHC 2+) or negative (IHC 0) breast cancer tissues using the
HER2 gene-protein assay. The HER2 gene-protein assay carried out on FFPE breast cancer tissue microarray slides was able to differentiate HER2
IHC 2+ cases that were HER2 & CEN17 BISH positive (A) and negative (B). It also distinguished HER2 IHC 0 cases that were HER2 & CEN17 BISH
positive (C) and negative (D). [All images 100×.].
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based on the HER2 & CEN17 BISH only assay.
Analyses of the combined HER2 IHC and HER2 &
CEN17 BISH data from each reader for the individual
IHC and BISH assays and the gene-protein assay are
shown in Table 7. For analyses using the HER2 gene-
protein assay, the status of a tissue core was defined as
HER2 positive if either the HER2 protein status was
positive or the HER2 gene status was amplified; other-
wise, it was defined as negative. This algorithm is con-
sistent with clinical practice, in which a patient is treatedFigure 5 Results of HER2 gene-protein staining of FFPE breast cancer
populations or isolated tumor cell populations. (A) The HER2 gene-pro
populations in FFPE breast cancer tissues. In the sample shown, cell popula
and all tumor populations present amplified HER2 gene. However, the HER
while the HER2 IHC 2+ and 1+ population contains clustered HER2 gene co
groups of HER2 IHC 3+ breast cancer cells [4×]. The insert shows an isolate
[100×].as HER2 positive if either assay shows an amplified
HER2 status. The results of the individual HER2 &
CEN17 BISH and HER2 IHC assays were similarly com-
bined to yield the overall HER2 status that served as the
reference for the combined assay. The HER2 positive
agreement ranged from 94.3% (Reader B) to 98% (Reader
A) and the HER2 negative agreement ranged from 97.5%
(Reader C) to 98.3% (Reader B). The overall agreement
ranged from 97.1% (Readers B and C) to 98.2% (Reader
A) and the kappa coefficient ranged from 0.93 (Readers
B and C) to 0.96 (Reader A), indicating that HER2tissues exhibiting heterogeneity of HER2 positive tumor cell
tein assay demonstrated the heterogeneity of HER2 positive tumor cell
tions with HER2 IHC scores of 3+, 2+, and 1+ neighbor each other
2 IHC 3+ tumor cell population contains dispersed HER2 gene copies
pies [40×]. (B) The HER2 gene-protein assay clearly visualized small
d individual HER2 IHC positive tumor cell with HER2 gene amplification









Total number of tissue cores 189
Number of tissue cores
without tumor
6
Number of cores with tumor 183
































IHC: immunohistochemistry; BISH: brightfield in situ hybridization.
Table 4 BISH descriptive statistics






































Median 2.200 2.225 1.900 1.900 2.000 1.950


























Median 1.650 1.750 1.500 1.450 1.550 1.550
Min, max 1.00, 3.50 1.00, 3.95 1.00, 2.80 1.00, 2.95 1.05, 2.60 1.00, 2.65
HER2/CEN17 ratio




























Amplification status, n (%)









N/A 4 (2.2) 17 (9.3) 4 (2.2) 11 (6.0) 3 (1.6) 10 (5.5)
BISH: brightfield in situ hybridization; HER2: human epidermal growth factor
receptor 2; CEN17: chromosome 17 centromere.
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http://www.diagnosticpathology.org/content/7/1/60diagnosis based on the BISH and IHC results of the
HER2 gene-protein assay is essentially equivalent to that
based on the separate HER2 & CEN17 BISH and HER2
IHC assays.
Analyses of the agreement among readers were per-
formed separately for the HER2 IHC protein statuses
from the single IHC assay and the gene-protein assay,
for the HER2 BISH gene statuses from the single assay
and the gene-protein assay, for the combined HER2 IHC
and HER2 & CEN17 BISH results from two separate
HER2 & CEN17 BISH and HER2 IHC assays and the
gene-protein assay (Table 8). Each of the three possible
reader pairs was assessed for each assay. Because no indi-
vidual reader was considered the reference, reader-to-
reader agreement was assessed by calculating APA and
ANA. Of the 24 calculated reader-to-reader agreement
rates, 17 were greater than 95%, 5 were between 90% andTable 3 IHC descriptive statistics






















IHC score, n (%)




1+ 47 (25.7) 43 (23.5) 34 (18.6) 26 (14.2) 18 (9.8) 14 (7.7)
2+ 10 (5.5) 8 (4.4) 7 (3.8) 6 (3.3) 8 (4.4) 10 (5.5)
3+ 42 (23.0) 42 (23.0) 43 (23.5) 42 (23.0) 47 (25.7) 44 (24.0)
IHC assessment, n (%)







IHC: immunohistochemistry.95%, and 2 were close to 90%, indicating excellent inter-
reader agreement on all assays. The APA and ANA for all
reader pairs based on HER2 IHC results, HER2 & CEN17
BISH results, and combined HER2 IHC and HER2 &
CEN17 BISH results were always higher in the HER2
gene-protein assay than in two separate HER2 IHC and
HER2 & CEN17 BISH assays and the difference ranged
from 0.1–5.6% (Table 9). Thus, when the HER2 & CEN17
BISH and HER2 IHC assays were combined into a single
test as the gene-protein assay, inter-reader agreement con-
sistently improved over two separate HER2 IHC and HER2
& CEN17 BISH assays.Discussion
To avoid subjecting breast cancer patients to unnecessary
financial burden and significant side effects, the selection
of those most likely to response to HER2-directed therapy
must be accurate. Our original motivation for developing
the tricolor HER2 gene-protein assay was to deliver a tis-
sue-based HER2 test that is more accurate than the
Table 5 Gene-protein IHC (comparator) vs. single IHC
(reference) agreement analyses
Single IHC
Gene-protein IHC Positive Negative Total
Reader A Positive 50 2 52
Negative 0 131 131
Total 50 133 183
PPA: n/N (%) (95% CI) 50/50 (100.0)
(92.9–100.0)
NPA: n/N (%) (95% CI) 131/133 (98.5)
(94.7–99.6)
OPA: n/N (%) (95% CI) 181/183 (98.9)
(96.1–99.7)
Kappa coefficient (95% CI) 0.97 (0.94–1.00)
Reader B Positive 47 3 50
Negative 1 132 133
Total 48 135 183
PPA: n/N (%) (95% CI) 47/48 (97.9)
(89.1–99.6)
NPA: n/N (%) (95% CI) 132/135 (97.8)
(93.7–99.2)
OPA: n/N (%) (95% CI) 179/183 (97.8)
(94.5–99.1)
Kappa coefficient (95% CI) 0.94 (0.89–1.00)
Reader C Positive 54 1 55
Negative 0 128 128
Total 54 129 183
PPA: n/N (%) (95% CI) 54/54 (100.0)
(93.4–100.0)
NPA: n/N (%) (95% CI) 128/129 (99.2)
(95.7–99.9)
OPA: n/N (%) (95% CI) 182/183 (99.5)
(97.0–99.9)
Kappa coefficient (95% CI) 0.99 (0.96–1.00)
IHC: immunohistochemistry; PPA: positive percent agreement; NPA: negative
percent agreement; OPA: overall percent agreement.
Table 6 Gene-protein BISH (comparator) vs. single BISH
(reference) agreement analyses
Single BISH
Gene-protein BISH Amplified Non-amplified Total
Reader A Amplified 43 2 45
Non-amplified 2 118 120
Total 45 120 165
PPA: n/N (%) (95% CI) 43/45 (95.6)
(85.2–98.8)
NPA: n/N (%) (95% CI) 118/120 (98.3)
(94.1–99.5)





Reader B Amplified 47 1 48
Non-amplified 3 121 124
Total 50 122 172
PPA: n/N (%) (95% CI) 47/50 (94.0)
(83.8–97.9)
NPA: n/N (%) (95% CI) 121/122 (99.2)
(95.5–99.9)






Reader C Amplified 41 5 46
Non-amplified 2 125 127
Total 43 130 173
PPA: n/N (%) (95% CI) 41/43 (95.3)
(84.5–98.7)
NPA: n/N (%) (95% CI) 125/130 (96.2)
(91.3–98.3)





BISH: brightfield in situ hybridization; PPA: positive percent agreement; NPA:
negative percent agreement; OPA: overall percent agreement.
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IHC assays are technically easier to perform than HER2
FISH assays, 80% of newly diagnosed breast cancer cases
in the US are analyzed for HER2 status using HER2 IHC
[12]. However, the technical issues that can complicate
HER2 IHC assays, such as unstandardized antigen re-
trieval protocols and multiple antibody clones, have led to
the recommendation of HER2 ISH as the first-line assay
for HER2 status assessment [13]. Tissue quality for HER2
ISH assays can be assessed using the ISH signals in normal
cells surrounding the tumor cells as internal controls. In
contrast, assessment of tissue quality for HER2 IHC assays
is difficult; because there is no proven internal control,
false negatives can result [14].
A 2007 report of the American Society of Clinical
Oncology-College of American Pathologists (ASCO-CAP)
concluded that 20% of HER2 assays performed in the fieldwere not accurate and established guidelines to improve
the accuracy of HER2 testing in breast cancer [2]. However,
a 2008 follow up study using survey results from 757 la-
boratories indicated that substantial gaps remained in assay
validation [15]. Lee et al. [1] also reported that only 15%
(7/46) of reported studies of the concordance between
HER2 IHC and HER2 FISH results achieved the ASCO-
CAP guideline of 95% or greater concordance.
Breast tumor heterogeneity is a major cause of discord-
ance between HER2 IHC and HER2 FISH assay results
[16,17] and approximately 5-30% of HER2 positive breast
cancer cases exhibit intratumoral genetic heterogeneity
[18]. Subtle HER2 genetic heterogeneity of tumor cells has
been reported among equivocal cases [17,19]. An alterna-
tive method for determining HER2 status from FFPE
Table 7 Gene-protein IHC/BISH (comparator) vs. single





Reader A Positive 50 2 52
Negative 1 112 113
Total 51 114 165
PPA: n/N (%) (95% CI) 50/51 (98.0)
(89.7–99.7)
NPA: n/N (%) (95% CI) 112/114 (98.2)
(93.8–99.5)
OPA: n/N (%) (95% CI) 162/165 (98.2)
(94.8–99.4)
Kappa coefficient (95% CI) 0.96 (0.91–1.00)
Reader B Positive 50 2 52
Negative 3 117 120
Total 53 119 172
PPA: n/N (%) (95% CI) 50/53 (94.3)
(84.6–98.1)
NPA: n/N (%) (95% CI) 117/119 (98.3)
(94.1–99.5)
OPA: n/N (%) (95% CI) 167/172 (97.1)
(93.4–98.8)
Kappa coefficient (95% CI) 0.93 (0.87–0.99)
Reader C Positive 52 3 55
Negative 2 116 118
Total 54 119 173
PPA: n/N (%) (95% CI) 52/54 (96.3)
(87.5–99.0)
NPA: n/N (%) (95% CI) 116/119 (97.5)
(92.8–99.1)
OPA: n/N (%) (95% CI) 168/173 (97.1)
(93.4–98.8)
Kappa coefficient (95% CI) 0.93 (0.88–0.99)
IHC: immunohistochemistry; BISH: brightfield in situ hybridization; PPA: positive
percent agreement; NPA: negative percent agreement; OPA: overall percent
agreement.
Note: IHC/BISH status: positive = IHC is positive or BISH is amplified;
negative = IHC is negative and BISH is non-amplified.











95.2% 97.2% 98.1% 98.8%
Single IHC 92.2% 96.2% 97.0% 98.5%
Gene-protein
BISH
93.5% 97.9% 97.7% 99.2%
Single BISH 88.2% 93.8% 95.5% 97.5%
Gene-protein
IHC/BISH
91.7% 95.2% 96.4% 98.0%
Single IHC/BISH 89.7% 94.3% 95.2% 97.3%
APA: average positive agreement; ANA: average negative agreement; IHC:
immunohistochemistry; BISH: brightfield in situ hybridization.
Table 9 Inter-reader agreement by reader pair and assay
Reader Pair Assay APA ANA
A vs. B Gene-protein IHC 96.1 98.5
Single IHC 93.9 97.8
Gene-protein BISH 97.9 99.2
Single BISH 93.8 97.5
Gene-protein IHC/BISH 95.2 98.0
Single IHC/BISH 93.3 96.9
A vs. C Gene-protein IHC 97.2 98.8
Single IHC 96.2 98.5
Gene-protein ISH 93.5 97.7
Single BISH 92.1 97.0
Gene-protein IHC/BISH 94.4 97.6
Single IHC/BISH 94.3 97.3
B vs. C Gene-protein IHC 95.2 98.1
Single IHC 92.2 97.0
Gene-protein BISH 93.8 97.7
Single BISH 88.2 95.5
Gene-protein IHC/BISH 91.7 96.4
Single IHC/BISH 89.7 95.2
APA: average positive agreement; ANA: average negative agreement; IHC:
immunohistochemistry; BISH: brightfield in situ hybridization.
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transcription-polymerase chain reaction (qRT-PCR) has
been proposed, but has not been approved by the FDA.
Based on a recent publication comparing the performance
of HER2 qRT-PCR-based testing with that of the FDA-
approved HER2 IHC and HER2 FISH methods [20], Igna-
tiadis and Sotirious have raised concerns about the use of
HER2 qRT-PCR for clinical diagnostics [21]. The HER2
qRT-PCR method failed to detect equivocal cases and
produced false negative results. Therefore, the need for
a better assay to assess HER2 status in breast cancer,
particularly in equivocal cases and in cases with tumor
heterogeneity, remains.
With an incidence of approximately 4%, HER2 false
negative (IHC negative and FISH positive) and false posi-
tive (IHC positive and FISH negative) results cannot be
ignored [1,17]. In one study, 9.7% (174/1787) of breast
cancer patients were HER2 false positive cases, but they
still benefited from adjuvant trastuzumab therapy [22]. In
another study, lapatinib therapy had significant positive
effects in FISH positive breast cancer patients whose IHC
tests had been 0, 1+, or 2+ [13]. Thus, the detection of
both false negative and false positive HER2 breast cancer
cases is important.
HER2 IHC assays are effective methods for detecting
tumor heterogeneity and equivocal cases based on HER2
protein staining under a light microscope, but these assays
are semi-quantitative and subjective. Thus, additional
quantitative gene analysis is required for equivocal cases
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missed if only HER2 IHC is applied while HER2 false posi-
tive cases will be missed if only HER2 ISH method is uti-
lized. Thus, the optimum HER2 testing protocol uses both
HER2 IHC and HER2 ISH assays [23].
To overcome the weaknesses of current HER2 tests,
we have successfully developed an automated brightfield
tricolor gene-protein assay for the detection of HER2
protein, the HER2 gene, and CEN17. The novel aspect
of the assay is the use of a blocker to prevent back-
ground staining caused by the binding of the DNP hap-
ten of the HER2 probe to tissue sections after they have
been processed through a DAB-based IHC assay. Al-
though three research groups have previously reported
the technical achievement of combining HER2 IHC and
single color brightfield HER2 ISH to co-visualize HER2
protein and the HER2 gene on FFPE breast cancer tissue
sections, all of these combined assays required several
manual steps for the ISH procedure.
The HER2 gene-protein assay described herein is a sig-
nificant improvement in the field because: 1) it demon-
strates tricolor co-localization of the HER2 protein,
HER2 gene, and CEN17 targets on well-preserved breast
cancer tissue sections and 2) it automates the entire
protocol of a gene-protein assay from deparaffinization
to counterstaining. Extensive analyses of the findings of
three pathologists with different levels of HER2 test
scoring experience for the combination HER2 gene-pro-
tein assay relative to those of the single HER2 IHC and
HER2 & CEN17 BISH assays revealed excellent concord-
ance. The statistical analysis suggests that the HER2
gene-protein assay is a robust and reliable assay and pro-
vides advantages over single HER2 IHC and HER2 &
CEN17 BISH assays.
Among the technical challenges we faced in develop-
ing the HER2 gene-protein assay was identifying an ap-
propriate multicolor scheme. Previously, Downs-Kelly
[7] and Ni et al. [8] used AP-based fast red staining of
HER2 protein followed by HRP-based silver or DAB
staining of HER2 gene, respectively. We evaluated AP-
based fast blue detection of HER2 IHC followed by the
HER2 BISH assay to obtain a tricolor detection scheme
in which HER2 protein was blue, the HER2 gene was
black, and CEN17 was red (data not shown), but this
scheme proved to be less than optimal; the pathologists
had difficulty scoring weak HER2 IHC staining because
the fast blue AP-based IHC staining was less crisp and
because both fast blue and hematoxylin counterstain are
blue. Therefore, because most pathologists are accus-
tomed to scoring DAB-based IHC detection for HER2
protein, we investigated a detection scheme using a
combination of conventional DAB-based detection of
HER2 protein and BISH detection of HER2 and CEN17
targets. The sequence of HER2 IHC and HER2 &CEN17 BISH staining was also evaluated to optimize
HER2 protein staining. As Reisenbichler et al. [9] previ-
ously noted, we observed weaker HER2 protein staining
when the HER2 IHC portion of the assay was performed
after the HER2 & CEN17 BISH portion of the assay
(data not shown). They compensated for the weaker
HER2 IHC staining by increasing the anti-HER2 anti-
body incubation time from 30 min to 45 min. In con-
trast, we determined that the HER2 IHC steps should be
performed first to maintain HER2 IHC staining quality,
particularly in cases with low expressed HER2 protein.
Reisenbichler et al. [9] also reported that they could not
obtain HER2 CISH signals when the CISH assay was per-
formed after HER2 IHC using DAB detection. We encoun-
tered a similar obstacle during the development of our
HER2 gene-protein assay, but primarily for CEN17 BISH
detection. We found that a longer protease digestion time
or a higher protease concentration was required to obtain
a consistent CEN17 BISH signal with difficult tissue sam-
ples to stain for CEN17 signals. As we have demonstrated
in this report, our optimized HER2 & CEN17 BISH assay
provided successful visualization of the HER2 gene and
CEN17 targets after DAB-based HER2 IHC.
Another major issue encountered during assay devel-
opment was a high level of silver background staining
from the silver-based HER2 BISH detection. The silver
background staining was observed mainly in the nuclei
and also some background staining was seen with DAB
staining. It did not occur when the DNP-labeled HER2
probe was omitted from the assay (data not shown).
Also, omission of the DAB chromogen and hydrogen
peroxide from the IHC procedure prevented silver
background staining from silver-based HER2 BISH
detection (data not shown). Therefore, we hypothesized
that there was an interaction between DAB and the
DNP hapten and the BISH detection for the DNP hapten
was responsible for the high levels of silver background
staining. Because extra washing after the HER2 IHC did
not eliminate the silver background staining (data not
shown), we concluded that the DAB molecules were co-
valently bound to the nuclear DNA.
It is well established that DAB is a carcinogen and that
carcinogenic agents bind to DNA. Oxidative intermediates
of the DAB analogue benzidine have been shown to form
covalent bonds to DNA, thereby localizing DAB in the cell
nucleus [24,25]. During the development of the HER2
gene-protein assay, the DNP-labeled probes appeared to be
binding to the peroxidase deposited DAB. The exact mech-
anism of this interaction is unknown, but electron-rich
aromatic compounds (such as DAB) and electron-deficient
aromatic compounds (such as DNP) are known to form
aromatic pi-stacks and/or charge transfer complexes [26].
Therefore, we speculated that another aromatic molecule
present in excess during hybridization would act as a
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the use of protein blockers in protein immunodetection to
prevent non-specific protein binding. After testing several
compounds with various electronic and aqueous solubility
properties (data not shown), we identified naphthol phos-
phate as a suitable blocker for use during hybridization
with DNP-labeled probes.
A HER2 gene-protein assay could be developed by com-
bining two darkfield assays, namely HER2 fluorescence
IHC and HER2 FISH assays. However, the current bright-
field HER2 gene-protein assay offers several advantages
over a darkfield gene-protein assay: 1) the ability to simul-
taneously observe the HER2 protein, HER2, and CEN17
targets in the context of tissue morphology; 2) the use of
an established scoring system for DAB-based HER2 IHC
assays; 3) the use of a regular light microscope for slide
observations, negating the need for a darkroom; 4) full
automation, which is optimal for reproducibility; and 5)
permanent preservation of both the IHC and ISH signals.
A HER2 gene-protein assay could also be developed using
DAB-based HER2 IHC and HER2 FISH assays. This assay
would have fewer disadvantages than the gene-protein
assay using fluorescence IHC, but would still require an
expensive fluorescence microscope and a darkroom. In
addition, long term preservation of the FISH signal would
be difficult and no completely automated protocol would
be available for this assay.
Conclusions
We have developed a robust automated procedure for
the simultaneous visualization of HER2 protein, the
HER2 gene, and CEN17 in FFPE xenograft tumor tissue
sections and have demonstrated its accuracy in the ana-
lysis of FFPE breast cancer TMA slides. The successful
multiplexing of two FDA-approved HER2 IHC and
HER2 & CEN17 BISH assays was achieved by the inclu-
sion of naphthol phosphate in the hybridization buffer
to eliminate the silver background staining resulting
from the HER2 BISH detection. This HER2 gene-protein
assay demonstrated the heterogeneity of HER2 protein
expression in breast cancer cell populations and the sim-
ultaneous detection of HER2 protein, the HER2 gene,
and CEN17 allowed differentiation of HER2 IHC 2+
cases to HER2 & CEN17 BISH positive or negative.
Furthermore, it correctly identified cases yielding false
negatives in HER2 IHC tests as HER2 & CEN17 BISH
positive. This new method for brightfield tricolor detec-
tion of HER2 protein, the HER2 gene, and CEN17 might
be useful in more accurately assessing the HER2 status
of breast cancer patients, particularly in equivocal cases
or cases with heterogeneous tumors. The HER2 gene-
protein assay might also be useful in gastric cancer,
which often exhibits tumor heterogeneity. Furthermore,
this strategy for gene-protein detection assays could beapplied to other cancer biomarkers, such as EGFR and
met proto-oncogene.
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